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ABSTRACT 
Draceana cinnabari (Dracaenaceae) is traditionally used in the treatment of wounds, leucorrhea, fractures, and diarrhoea. Herein, we performed 
a pre-clinical safety evaluation of extract of Draceana  cinnabari resin on Spradgue Dawley rats. Toxicological codicil of the extract was carried 
out following OECD guidelines 423 and 407, with minor changes. DC resin methanol extract administered to the rats by oral gavage at 50, 500, 
1500, and 2500 mg/kg body weight daily up to 28 days to male and female rats. Herbal extract could most likely be very much endured up to the 
dose 2000 mg/kg body weight and could be named Category 4. Oral toxicity studies confirm that Draceana  cinnabari has no therapy-related 
demise or toxic signs on rats. Therefore, the resin, ought to be suitably considered for additional research for its medicinal and therapeutic 
efficacy. 
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Medicinal plants, either as an extract, pure compound, or as a 
derivative, offer unlimited opportunities for the discovery of 
new drugs. Most of the natural products used in folk remedy 
have solid scientific evidence about their biological activities. 
However, there is little information or evidence available 
concerning the possible toxicity that medicinal plants may 
cause to consumers1 . Toxicity is a terminology used to 
describe the property of being poisonous or indicate the 
state of detrimental outcomes by means of the interaction 
between toxicants and cells. This mechanism of action may 
likewise change depending on the cell membrane and 
chemical residences of the toxicants. It may occur inside the 
cell membrane or on the cell surface or tissue beneath as 
well as at the extracellular matrix. In most of the occurrence, 
visceral organs such as liver, lung and kidney are affected via 
the toxicants2 . 
Many studies have already shown that several medicinal 
plants have detrimental effects. The customary use of any 
plant for the ameliorative outcome, itself does not guarantee 
the safety of that plant. Thus, data of the acute and sub-
chronic toxicity studies on medicinal plants or their 
preparations should be obtained to increase the confidence 
in their safety to humans, particularly for use in the 
development of pharmaceuticals3. 
Dragon’s blood is a name applied to resins obtained from 
plants like Dracaena, Daemonorops, Croton and Pterocarpus. 
There are many types of chemical constituents in Draceana 
cinnabari (Dracaenaceae) resin (Figure 1), including 
flavones, saponins, steroids and volatile oils. 4,5  
 
Figure 1: Dracaena cinnabari resin 
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Pharmacological investigations indicate that it can inhibit the 
aggregation of platelets, venous thrombosis and bacterial 
action. It additionally has anti-inflammatory, analgesic and 
homeostatic effect.6,7  Recently, Dracaena has been clinically 
used for treatment of cerebral arterial thrombosis, ischemic 
heart disease and peptic ulcer 8.  However, not much work 
has been done of its safety profile by toxicity studies The 
purpose of this work is to explore the acute and chronic 
toxicity profile along with the antioxidant properties of D. 
cinnabari resin extract. 
MATERIALS AND METHODS  
Plant material 
Dracaena cinnabari resin used in this study was procured 
from the local bazaar Ballimaran, Delhi, India. A voucher 
specimen (NISCAIR/RHMD/Consult/2008-09/1192/224) of 
the resin was collected, identified and deposited at NISCAIR, 
New Delhi, India  
Chemical reagents 
All the chemicals used in this study were obtained from Hi-
Media Laboratories Pvt. Ltd. (Mumbai, India), Sigma-Aldrich 
Chemical Co. (Milwaukee, WI, USA), and SD Fine-Chem. Ltd. 
(Mumbai, India). All the chemicals used in this study were of 
analytical grade. 
Preparation of plant extracts 
The crude extracts were prepared by cold maceration 
technique 9. The extraction was done by refluxing 300 g of 
resin in 2400ml of methanol (98%) and placing the mixture 
on an orbital shaker (at 160rpm) for 72 hrs. The mixture was 
concentrated in a rotary evaporator. The resulting extract 
(DRE) was lyophilised and stored in an amber coloured 
airtight container at 4°C until further use. 
Selection and Procurement of animals 
Experimental animals 
For acute and subacute oral toxicology assessment, (total of 
65), age (6 weeks) and weight (129.1 to 140.2 gm) matched 
female and male Sprague Dawley (SD) pathogen-free rats 
were used. Fifteen female rats were used for an acute oral 
toxicity test; furthermore forty rats (twenty-five males and 
twenty-five females) were used for acute oral toxicity tests 
(twenty-eight days of recurrent dose). The toxicity tests 
were carried out according to Organization for Economic 
Cooperation and Development (OECD) test guideline, 
specifically OECD Guideline 423 for the acute oral toxicity 
test10  and OECD Guideline 407 for the sub-acute oral toxicity 
test11  with slight modifications. All animals were procured 
and housed in animal house maintained under standard 
hygienic conditions. Animals were acclimatised to the 
laboratory environment for seven days ahead of the 
experiments. The animals were allowed free to access 
commercial rat pellet diet (Lipton India Ltd, Mumbai, India) 
and water ad libitum. The bedding materials of the enclosure 
were changed every day. All the experimental trial was 
carried out in conformity with the CPCSEA guidelines. The 
study design was approved by the Institutional Animal 
Ethics Committee (IAEC) of Pinnacle Biomedical Research 
Institute (PBRI) (Reg No. CPCSEA Reg. No. 
1283/c/09/CPCSEA).  Bhopal (MP), India. Protocol approval 
reference no. PBRI/11/IAEC/PN-209. 
Acute toxicity  
Animals were randomly divided in the group (n=3), a control 
group (Group A) and dose levels (Groups A1, A2, A3 and A4, 
administered respectively 50mg, 500mg, 1500mg and 2500 
mg DRE / kg body weight). DRE was given once by oral 
gavage at a weight of 10 mL/kg body weight. The control 
animals have been treated with distilled water in the same 
volume. Animals were observed for three hours after dose 
administration changes in behaviour. The rats were weighed, 
and visual observations for mortality, behavioural pattern 
(salivation, fur, lethargy, and sleep), changes in physical 
appearance, injury, pain, and any signs of illness were 
conducted once daily during of 24 and 48 hours. 
Sub-chronic Toxicity 
The remaining forty male and female SD rats (n = 5 males 
and 5 females/group) were arbitrarily divided into a control 
(Group SC) and three dose teams (GroupSC1, SC2, SC3, and 
SC4 administered fifty, five hundred, fifteen hundred and 
twenty-five hundred mg/kg body weight/day, respectively). 
The standard procedures were followed as per the OECD 407 
guidelines (OECD, 143 2008). DRE was administered once 
daily for four weeks, by oral gavage of 10 mL/kg body 
weight. Control animals have only been,  treated with the 
same quantity of distilled water during the four weeks assay 
period.  
The dosage was freshly prepared on a day to day basis. The 
rodents were weighed. Rats observed visually for morbidity, 
changes in behaviour ( like dormancy,  fur, rest and 
salivation), changes in physical appearance, damage,  agony 
and malady were done once a day during that period. 
Animals were fasted overnight at the end of the treatment, 
albeit with water ad libitum. Blood samples were collected 
thru retro-orbital puncture employing capillary tubes for 
haematological and biochemical research along with 
anticoagulant EDTA. All rats were anaesthetised with 
isoflurane and afterwards sacrificed through 
exsanguinations from carotid and jugular vessels. 12 
Complete postmortem examination was carried out on all 
animals. 
Analogous organ weight determination: 
Organs, that is liver and kidneys were meticulously 
eviscerated from the rats immediately after sacrifice and 
weighed in grams. The comparative organ weight of each 
animal was then quantified as follows: 
Relative organ weight = absolute organ weight (g) × 100/ 
body weight of rat on sacrifice day (g) 
Haematology and serum biochemistry: 
Haematological and biochemical studies of liver function, 
plasma constituents, and electrolyte concentrations were 
determined using standard clinical procedures. 
Haematological parameters 
For complete blood count, 3.0 ml of venous blood was taken 
in a vacutainer tube containing EDTA as an anticoagulant. 
Basic haematological estimated  were haemoglobin (Hb) 
content, red blood cell (RBC), total white blood count (WBC), 
and differential WBC count (neutrophil, eosinophil, basophil, 
lymphocyte and monocyte), as well as  platelet count, were 
performed using an automated analyzer Automatic Hemato 
analyzer (MS-4) (Melet Schloesing Laboratories, Osny, 
France)).13  
Serum biochemical parameters, which were measured from 
serum using kits (Span Diagnostic Ltd., Surat, Gujarat, India 
using a UV-VIS Spectrophotometer (Shimadzu, Tokyo, 
Japan). Serum biochemical parameters included total serum 
protein (TP), creatinine (CREA), blood urea nitrogen (BUN), 
albumin (ALB),   alkaline phosphatase (ALP), glutamate 
oxaloacetate transaminase (GOT), and glutamate pyruvate 
transaminase(GPT)14 . 
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Histopathology 
Organs were fixed and preserved in 10% phosphate-buffered 
formalin. Tissues were fixed by embedding in paraffin, 
sectioned, and stained with hematoxylin and eosin. Collected 
tissues were grossly and microscopically examined15.  
Statistical analysis 
The results were expressed as mean ± SEM (n = 5). Data 
acquired as of hematology analysis, serum biochemistry, as 
well as the body and organ weight measurements were 
articulated as mean + SD and evaluated by unpaired t test (2-
tailed P value) to compare the mean of the treated group of 
each sex with the control.Data were analysed using Student’s 
t-test, and results were considered significant when p < 0.05. 
 
Table 1: General appearance and behavioural observations for control and treated groups in Acute toxicity study of DCE (n = 5). 
Observation 
3 Hours 24 hours 48 hours 
A A1 A2 A3 A4 A A1 A2 A3 A4 A A1 A2 A3 A4 
Behavioural 
patterns 
* * * * * * * * * * * * * * * 
Coma * * * * * * * * * * * * * * * 
Diarrhea * * * * * * * * * * * * * * * 
Eyes * * * * * * * * * * * * * * * 
Lethargy * * * * * * * * * * * * * * -- 
Mucous * * * * * * * * * * * * * * * 
Salivation * * * * * * * * * * * * * * * 
Skin and fur * * * * * * * * * * * * * * * 
Sleep * * * * * * * * * * * * * * * 
Tremors * * * * * * * * * * * * * * * 
Dosing Groups   A=Control group   A1=5mg/kg group   A2=50mg/kg group   A3=300mg/kg group   A4=2000mg/kg group   *= 
Normal    --= not normal  
 
Table 2: Effect of DRE on body weight (g), organ (liver and kidney) as well as relative organ weight of (female) rats (n = 5). 
Group 
Body Weight (g) 
Absolute weight (g) 
 
Relative weight 
(g/100g body weight) 
Liver Kidney Liver Kidney 
Day “0” Day “07” Day “14” Day “28” Day “28” Day “28” Day “28” Day “28” 
SC 125.4±4.5 183.5±7.3 231.9±8.4 289.6±5.7 6.37 ±0.51 0.89 ± 0.36 2.21 ±0.13 0.31±0.03 
SC1 126.1±5.1 182.7±4.8 230.7±8.6 288.8±7.7 6.35± 0.39 0.92 ± 0.42 2.20 ±0.11 0.32±0.02 
SC2 125.3±8.1 182.6±7.6 232.7±9.6 290.3±3.5 6.33± 0.10 0.89 ± 0.85 2.18 ±0.14 0.31±0.04 
SC3 123.2±6.1 184.2±1.8 230.1±3.7 289.1±6.3 6.40± 0.30 0.98 ± 0.40 2.14 ±0.12 0.34±0.02 
SC4 124.1±2.1 183.4±3.9 229.7±8.6 288.1±3.2 6.43± 0.25 0.92 ± 0.32 2.19 ± 0.13 0.32±0.03 
Values are presented as the mean±standard deviation 
Dosing Groups SC= Control SC1 SC2 SC3 SC4 
 
Table 3: Effect of DRE on body weight (g), organ (liver and kidney) as well as relative organ weight of (male) rats (n = 5). 
Group 
Body Weight 
Absolute liver weight (g) 
Relative kidney weight 
(g/100g body weight) 
Liver Kidney Liver Kidney 
Day “0” Day “07” Day “14” Day “28” Day “28” Day “28” Day “28” Day “28” 
SC 153.4±6.5 236.5±8.3 310.9±7.4 394.6±4.9 10.73±0.18 1.34± 0.32 2.72±0.13 0.34 ± 0.01 
SC1 153.4±5.7 235.9±4.1 311.0±5.6 395.2±3.2 10.90±0.17 1.42± 0.45 2.76±0.12 0.36 ± 0.02 
SC2 154.1±6.3 235.9±4.1 310.5±7.9 394.3±5.7 10.53±0.19 1.33± 0.60 2.67±0.10 0.34 ± 0.01 
SC3 154.6±1.9 235.9±4.1 310.1±4.9 392.1±2.7 10.59±0.18 1.29± 0.55 2.70±0.14 0.33 ± 0.03 
SC4 152.7±9.7 234.6±3.9 309.7±6.7 393.7±3.5 10.82±0.24 1.37± 0.20 2.75±0.11 0.35 ± 0.01 
Values are presented as the mean±standard deviation 
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SC 1.9 ± 0.8 13.4 ± 0.4 78.7 ± 5.7 3.1 ± 1.2 15.8 ± 5.0  1071 ± 125  7.47 ± 0.33  3.17 ± 0.63  
SC1 2.1 ± 0.4 14.3 ± 0.3** 78.9 ± 4.5 3.1 ± 1.0 15.4 ± 4.3  990 ± 114  7.93 ± 0.28**  3.81 ± 1.03  
SC2 2.0± 0.6 14.0 ± 0.6* 77.2± 3.7 2.9 ± 0.4 15.0 ± 3.8 1020 ± 116 7.74 ± 0.16* 3.88 ± 1.06 
SC3 1.9 ± 0.5 13.8 ± 0.5 78.4 ± 4.6 3.4 ± 0.5 14.9 ± 4.1  1038 ± 123  7.63 ± 0.24  3.99 ± 1.07  
SC4 1.8 ± 0.7 13.9 ± 0.4* 80.0 ± 5.6 4.0 ± 1.5 14.8 ± 5.5 1040 ± 128 7.66 ± 0.20 4.05 ± 0.83 
Values are presented as the mean±standard deviation 
Dosing Groups SC= Control SC1 SC2 SC3 SC4 
EO, Eosinophil;  HB, Hemoglobin concentration; LY, Lymphocyte; MO, Monocyte; NE, Neutrophil;PLT, Platelet count; RBC, Red 
blood cell count,   WBC, White blood cell count  . 
 
Table 5: Serum biochemical data of female SD rats treated orally with DRE for 4 weeks (n = 5) 
Group ALB (g/dL) ALP (U/L) ALT (IU/L) AST (IU/L)  BUN (mg/dL) CREA mg/dL) TP (g/dL) 
SC 3.1 ± 0.2 139 ± 28  34 ± 11  86 ± 22  16.3 ± 1.9  0.6 ± 0.0  6.8 ± 0.2  
SC1 3.0 ± 0.2 147 ± 24  36 ± 12  96 ± 26  15.8± 1.6 0.6 ± 0.0 6.6 ± 0.3  
SC2 2.8± 0.1 150 ± 24  33 ± 14 91 ± 31 15.5 ± 2.0  0.6 ± 0.0 6.7 ± 0.4 
SC3 2.9 ± 0.1 156 ± 35 30 ± 9  87 ± 18  15.2 ± 1.4  0.6 ± 0.1  6.8 ± 0.4   
SC4 3.1 ± 0.2 156 ± 35 30 ± 9 87 ± 18 15.2 ± 1.4 0.6 ± 0.1 6.7 ± 0.2 
Values are presented as the mean±standard deviation 
Dosing Groups SC= Control SC1 SC2 SC3 SC4 
ALB, albumin;   ALP, alkaline phosphatase; ALT, ala- nine aminotransferase; AST, aspartate aminotransferase;  BUN, blood urea 
nitrogen; CREA, creatinine; TP, total protein; 
 
Table 6 Hematological s data of male SD rats treated orally with DRE for 4 weeks (n = 5) 









Plt (103/µL) RBC (106/µL) WBC (103/µL) 
SC 1.3 ± 0.6  14.6 ± 0.7  80.4 ± 5.7  2.2 ± 1.1  15.7 ± 4.6  1001 ± 62  8.44 ± 0.37  6.94 ± 1.30  
SC1 1.4 ± 0.4  14.3 ± 0.5  79.2 ± 4.8  2.4 ± 0.6  16.6 ± 4.4  1006 ± 73  8.47 ± 0.25  7.26 ± 1.88  
SC2 1.5 ± 0.5 14.3 ± 0.9 77.6 ± 6.2 2.6 ± 0.4 17.7 ±5.6 990 ± 59 8.35 ± 0.21 6.42 ± 1.56 
SC3 1.6 ± 0.7  14.4 ± 0.3  76.3 ± 7.2  2.7 ± 0.9  18.9 ± 6.3  998 ± 78  8.27 ± 0.24  5.83 ± 1.56  
SC4 1.5 ± 0.6 14.5 ± 0.2 79.3 ± 4.8 2.4 ± 0.7 16.4 ± 3.9 1045 ± 160 8.46 ± 0.23 5.81 ± 0.95 
Values are presented as the mean±standard deviation 
Dosing Groups SC= Control SC1 SC2 SC3 SC4 
EO, Eosinophil;  HB, Hemoglobin concentration; LY, Lymphocyte; MO, Monocyte; NE, Neutrophil;PLT, Platelet count; RBC, Red 
blood cell count,   WBC, White blood cell count  . 
Table 7: Serum biochemical data of male SD rats treated orally with DRE for 4 weeks (n = 5) 
Group ALB (g/dL) ALP (U/L) ALT (IU/L) AST (IU/L)  BUN (mg/dL) CREA mg/dL) TP (g/dL) 
SC 2.5 ± 0.1  287 ± 45  32 ± 4  101 ± 26  14.9 ± 2.1  0.6 ± 0.1  6.1 ± 0.2  
SC1 2.4 ± 0.1 285± 41 33 ± 6  95 ± 23  14.8 ± 1.7 0.6 ± 0.1  6.0 ± 0.2  
SC2 2.3 ± 0.6 284 ± 31  32 ± 4  95 ± 46 14.3 ± 2.3 0.6 ± 0.1 6.0 ± 0.2 
SC3 2.4 ± 0.1 296 ± 76 31 ± 6  96 ± 19  13.8 ± 2.1  0.6 ± 0.1  6.0 ± 0.2  
SC4 2.5 ± 0.1 276 ± 46 32 ± 8 95 ± 22 13.3 ± 1.5 0.5 ± 0.1 6.0 ± 0.3 
Values are presented as the mean±standard deviation 
Dosing Groups SC= Control SC1 SC2 SC3 SC4 
ALB, albumin;   ALP, alkaline phosphatase; ALT, ala- nine aminotransferase; AST, aspartate aminotransferase;  BUN, blood urea 
nitrogen; CREA, creatinine; TP, total protein; 
 
RESULTS  
Acute Toxicological Studies   
In the present investigation, we assessed the likely toxicity 
and 50% lethal dose (LD50) of DRE following a regiment of 
solitary oral to female rodents. DRE was orally administered 
once at doses of  50mg, 500mg, 1500mg and 2500 mg  DRE / 
kg body weight to SD rats. Mortality, clinical signs, and body 
weight changes were observed for 120 hours days after 
administration. No deaths in any animals were observed 
during the experimental period. No test substance-related 
effects were evident concerning clinical signs, body weight 
changes, and necropsy findings at all dosages as shown in 
Table 1. These results suggest that acute exposure to DRE 
does not cause toxic effects, and its LD50 value is considered 
to be greater than 2500 mg/kg in rats. 
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Sub-chronic Toxicological Studies  
No toxicity signs (such as piloerection, alteration in the 
locomotor activity or food and water consumption) or deaths 
were recorded during the 28 consecutive days of treatment 
by oral route with D. cinnabari resin extract in doses fifty, 
five hundred, fifteen hundred and twenty-five hundred 
mg/kg body weight/day, respectively). As expected, the rat’s 
body weight increased with time. Equally, no significant 
changes were recorded in body weight gain of control and 
treated rats (Table 2 and 3). However, the rats treated with 
DRE did present mild diarrhoea at some point in the period 
of treatment, portentous of a laxative effect of the extract. 
The treatment with a hydro-alcoholic extract of D. cinnabari 
for 28 days did not alter the biochemical profile of female 
and male S D rats, as shown in Tables 5 and 7, respectively. 
Haematological analysis 
In the same way, the haematological profile of female (Table 
4) and male rats (Table 6) was not altered by treatment with 
DRE. In both biochemical and haematological studies, all 
values in control and treated groups were within the 
reference range for the species. 
DISCUSSION  
Herbal medicines are used worldwide for the treatment and 
prevention of various acute and chronic diseases and are 
gaining popularity in developing countries. Herbal medicines 
are often believed to be harmless because they are “natural” 
and are easily available and commonly used for self-
medication without supervision. These medicines contain 
7bioactive constituents with potential to cause adverse 
effects. 16, 17. The results of the present study suggested that 
D. cinnabari  is a relatively nontoxic plant. During 120 hours 
period of acute toxicity evaluation, rats were not associated 
with any mortalities and abnormalities in general conditions, 
behavior and growth, feed and water consumption of 
animals. Body weight changes are indicators of adverse side 
effects, as the animals that survive cannot lose more than 
10% of the initial body weight 18. Body weight gain and feed 
consumption levels were similar in both control and treated 
animals. 
ALP, ALT, AST in tissue and blood are important marker 
enzymes which are used to assess the integrity of the cell 
membrane, cytosolic activity and cell death 19. The extent of 
hepatocellular injury is assessed by the increased serum 
levels of ALP, ALT, and AST .The study results indicate that 
the value of marker enzymes was within normal permissible 
limits and same was observed in case of various 
hemaetological parameters. 
CONCLUSION  
In conclusion, the DRE was well tolerated, lack of mortality 
and neither produced overt signs of clinical toxicity ( loss of 
hair, behavioral changes, impairments in feed intake and 
body weight gain), nor any signs of hepato-, nephro-, or 
haematotoxicity, also well supported by biochemical data. 
This acute toxicity study suggests that the extract of D. 
cinnabari resin is safe up to the dose of 2500mg/ kg b.w. 
especially when consumed by oral route. Further studies in 
repeated doses (sub-acute and chronic) must be performed 
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